Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999335 · ClinicalTrials.gov registry record · Phase 1
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01999335 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 33 participants.
The verdict
NCT01999335, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of the Phase 1 part of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of oprozomib in combination with pomalidomide and dexamethasone in adults with primary refractory or relapsed and refractory multiple myeloma. The purpose of the Phase 3 part of the study is to compare the efficacy for adults with primary refractory or relapsed and refractory multiple myeloma who are randomized to either oprozomib or placebo in combination with pomalidomide and dexamethasone.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Oprozomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-07-30 |
| Est. Completion | 2019-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999335
The ClinicalTrials.gov registry entry for NCT01999335 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01999335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999335 about?
NCT01999335 is a clinical study titled "A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma". The purpose of the Phase 1 part of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of oprozomib in combination with pomalidomide and dexamethasone in adults with primary refractory or relapsed and refractory multiple myeloma. The purpose of the ...
What is the current status of trial NCT01999335?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2014-07-30. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT01999335?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Oprozomib (DRUG).
Who is sponsoring clinical trial NCT01999335?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.